In this paper, a design method for a linearly polarized antenna is proposed by combining the principle of optical holography and the structure of a center-fed parallel-plate waveguide. By loading the ...

Volkswagen Commercial Vehicles has developed a new plug-in hybrid all-wheel drive system for the Multivan and California: the ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that employs its in-house base-editing technology to lead the way in precision genetic medicine.

Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

New data from the BEACON trial with more patients and longer follow-up provide further demonstration of the strong clinical profile for the investigational base-editing therapy BEAM-101, as ...

About BEAM-101 BEAM-101 is an investigational genetically modified cell therapy for the treatment of severe sickle cell disease (SCD).

Scientists have developed a technique that aligns stem cells into a single sheet, resulting in a marked increase in the secretion of signaling proteins which help repair tissue and regulate the immune ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

This paper considers the problem of beam alignment in a cell-free massive MIMO deployment with multiple access points (APs) and multiple user equipments (UEs) simultaneously operating in the same ...

Getting the right feed to the right cow is always a challenge, but having inaccurate or non-functioning load cells on TMR mixers make that task almost impossible. Diamond V feed specialists checked ...